CS INSIGHTS BIOTECH MARKET / BUSINESS INTELLIGENCE Sotio 10/7/2021 May 2021 Review of news from the most innovative therapeutic areas and the business development transactions by Jakub Jarolím, Business Intelligence Department SOTIO MARKET Proposed new US Government body ARPA-H is raising both hopes and skepticism Proposed new US government body Advanced Research Projects Agency – Health should be antidote to bureaucracy and incrementalism that some patient advocates believe prevents NIH from turning an investment of over $50 billion per year into transformative medicines. Critics warn that after initial enthusiasm fades, funding ARPA-H could cut into NIH’s budget. Numerous stocks were negatively influenced by quarterly financial results announced during May. NEWS DETAIL ANTIBODY-DRUG CONJUGATES Seagen and Astellas announced updated results from two trials on Padcev The partners announced updated results from two clinical trials examining Padcev (enfortumab vedotin-ejfv) alone (EV-201 Cohort 2) and Padcev in combination with Keytruda (EV-103 Cohort A) in patients with locally advanced or metastatic urothelial cancer who are not able to receive cisplatin chemotherapy. The data will be presented at ASCO. NEWS DETAIL INTERLEUKIN-15 AND INTERLEUKIN-2 ImmunityBio announced positive results of Anktiva with Rituxan in relapsed NHL patients ImmunityBio announced publication of results from its Phase 1 study evaluating Anktiva (N-803), its IL-15 superagonist, in combination with Rituxan, an anti-CD20 monoclonal antibody therapy, in patients with indolent NHL, who had relapsed or were refractory after two lines of therapy. NEWS DETAIL CELL THERAPIES Autolus presented new data on AUTO1 in relapsed or refractory indolent B cell lymphomas Autolus has linked its CD19 CAR-T to a 100% complete response rate in a small indolent B-cell lymphoma trial. AUTO1 drove the responses without causing any grade 3 or worse cytokine release syndrome, sending shares in the biotech up 35%. NEWS DETAIL OTHER INNOVATIVE TREATMENT AREAS Approvals: FDA grants accelerated approval to Keytruda for HER2-positive gastric cancer FDA granted accelerated approval to Keytruda in combination with Herceptin, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic HER2 positive gastric or gastroesophageal junction adenocarcinoma. NEWS DETAIL OTHER INNOVATIVE TREATMENT AREAS Clinical: LAG3 to steal the spotlight from TIGIT at this year’s ASCO The ASCO conference is set to deliver promising readouts for several compounds targeting LAG3 including data from BMS that could lead to the first registrational filing for a next-generation checkpoint blocker. NEWS DETAIL ONCOLOGY TRANSACTIONS Athenex agreed to acquired Kuur for $185 million adding CAR-NKT platform Selected M&As and Partnering NEWS DETAIL DISCLAIMER / SOTIO Legal notice NEWS DETAIL Share on social networks NEWS TO EMAIL Get the latest press releases, interviews, podcasts, and insights. SUBSCRIBE TO NEWS FOLLOW US FOR MEDIA For Media Press Releases Interviews and Podcasts Subscribe To News Downloads Contacts MAY BE OF INTEREST Our Companies Newsroom Insights CONTACTS PPF Group Companies TERMS OF USE DATA PROTECTION SITEMAP COOKIES POLICY COOKIES SETTINGS 2021 © PPF GROUP Cookies Consent We are using cookies for the best experience on our websites. For more information visit our document Information about cookies on the "Cookies settings" menu. By clicking accept all cookies you agree with our use of all the types of cookies. If you want to alter the types of cookies, you can do this in our "Cookies settings" menu. By clicking "Deny cookies" you are refusing all cookies, except cookies necessary for website functionality. Information about cookies Cookies Settings Deny Cookies Accept All Cookies